R C Turner

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    R C Turner
    Radcliffe Infirmary, Oxford, England
    JAMA 281:2005-12. 1999
  2. ncbi Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
    A L Gloyn
    Diabetes Research Laboratories, Nuffield Department of Clinical Medicine, University of Oxford, Radcliffe Infirmary, Oxford, UK
    Diabet Med 18:206-12. 2001
  3. ncbi A novel point mutation in the insulin gene giving rise to hyperproinsulinemia
    M G Warren-Perry
    Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, England
    J Clin Endocrinol Metab 82:1629-31. 1997
  4. ncbi Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects
    A Clark
    Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, England
    Cell Tissue Res 257:179-85. 1989
  5. ncbi Linkage of type 2 diabetes to the glucokinase gene
    A T Hattersley
    Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford, UK
    Lancet 339:1307-10. 1992
  6. ncbi Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4
    P J Kaisaki
    Howard Hughes Medical Institute, Department of Biochemistry, University of Chicago, Illinois 60637, USA
    Diabetes 46:528-35. 1997
  7. ncbi Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM
    H Inoue
    Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Diabetes 46:502-7. 1997
  8. ncbi Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro
    H Sakura
    University Laboratory of Physiology, Oxford, UK
    Diabetologia 39:1233-6. 1996
  9. ncbi Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes
    M Stoffel
    Howard Hughes Medical Institute, University of Chicago, Illinois 60637
    Nat Genet 2:153-6. 1992
  10. ncbi Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients
    G J Cooper
    Department of Biochemistry, University of Oxford, United Kingdom
    Proc Natl Acad Sci U S A 84:8628-32. 1987

Collaborators

Detail Information

Publications13

  1. ncbi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    R C Turner
    Radcliffe Infirmary, Oxford, England
    JAMA 281:2005-12. 1999
    ..8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown...
  2. ncbi Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
    A L Gloyn
    Diabetes Research Laboratories, Nuffield Department of Clinical Medicine, University of Oxford, Radcliffe Infirmary, Oxford, UK
    Diabet Med 18:206-12. 2001
    ..Secondly, novel and previously described variants associated with Type 2 diabetes (SUR1 exon 16-3t, exon 18 T, and Kir6.2 E23K) were investigated in the UKPDS cohort...
  3. ncbi A novel point mutation in the insulin gene giving rise to hyperproinsulinemia
    M G Warren-Perry
    Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, England
    J Clin Endocrinol Metab 82:1629-31. 1997
    ..The G1552C mutation was not linked with diabetes, because it was present in a 37-yr-old nondiabetic daughter and not in a 35-yr-old daughter who had had gestational diabetes...
  4. ncbi Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects
    A Clark
    Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, England
    Cell Tissue Res 257:179-85. 1989
    ..Abnormal processing of the peptide within B-cells could lead to the formation of islet amyloid in type-2 diabetes...
  5. ncbi Linkage of type 2 diabetes to the glucokinase gene
    A T Hattersley
    Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford, UK
    Lancet 339:1307-10. 1992
    ..Defects in the glucokinase gene may play an important part in the pathogenesis of type 2 diabetes...
  6. ncbi Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4
    P J Kaisaki
    Howard Hughes Medical Institute, Department of Biochemistry, University of Chicago, Illinois 60637, USA
    Diabetes 46:528-35. 1997
    ..The information on the sequence of the HNF-1alpha gene and its promoter region will facilitate the search for mutations in other subjects and studies of the role of the gene in determining normal beta-cell functions...
  7. ncbi Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM
    H Inoue
    Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Diabetes 46:502-7. 1997
    ..Diabetes 45:825-831, 1996) and 2) did not contribute to the impaired insulin secretion characteristic of NIDDM in Caucasian patients...
  8. ncbi Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro
    H Sakura
    University Laboratory of Physiology, Oxford, UK
    Diabetologia 39:1233-6. 1996
    ..We therefore conclude that mutations in Kir6.2 are unlikely to be a major cause of NIDDM...
  9. ncbi Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes
    M Stoffel
    Howard Hughes Medical Institute, University of Chicago, Illinois 60637
    Nat Genet 2:153-6. 1992
    ....
  10. ncbi Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients
    G J Cooper
    Department of Biochemistry, University of Oxford, United Kingdom
    Proc Natl Acad Sci U S A 84:8628-32. 1987
    ..The accumulation of amyloid, including diabetes-associated peptide, in islets may impair islet function in type 2 diabetes mellitus...
  11. ncbi Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms
    S O'Rahilly
    Department of Medicine, Beth Israel Hospital, Boston, Massachusetts 02215
    Diabetes 40:777-82. 1991
    ..SSCP analysis is a sensitive rapid method for screening for mutations in the insulin-receptor gene.(ABSTRACT TRUNCATED AT 250 WORDS)..
  12. ncbi Dinucleotide repeat polymorphism at the human GLUT2 locus
    P Patel
    Department of Haematology, John Radcliffe Hospital, Headington, Oxford, UK
    Nucleic Acids Res 19:4017. 1991
  13. ncbi UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
    Diabetologia 44:156-63. 2001
    ..CONCLUSION/INTERPRETATION: The findings re-emphasise the need for good glycaemic control and assiduous treatment of hypertension if diabetic retinopathy is to be minimised...